211 related articles for article (PubMed ID: 36839941)
21. Target molecules for future hidradenitis suppurativa treatment.
Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; Del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP
Exp Dermatol; 2021 Jun; 30 Suppl 1():8-17. PubMed ID: 34085329
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
23. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
[TBL] [Abstract][Full Text] [Related]
24. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
[TBL] [Abstract][Full Text] [Related]
25. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
26. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa.
Haferland I; Wallenwein CM; Ickelsheimer T; Diehl S; Wacker MG; Schiffmann S; Buerger C; Kaufmann R; Koenig A; Pinter A
Exp Dermatol; 2022 Jul; 31(7):1005-1013. PubMed ID: 35048417
[TBL] [Abstract][Full Text] [Related]
28. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
29. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.
Malvaso D; Calabrese L; Chiricozzi A; Antonelli F; Coscarella G; Rubegni P; Peris K
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896210
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
31. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
32. Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa.
Frings VG; Jopp L; Srivastava M; Presser D; Goebeler M; Schmidt M
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2488-2498. PubMed ID: 35881108
[TBL] [Abstract][Full Text] [Related]
33. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
[TBL] [Abstract][Full Text] [Related]
34. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
[TBL] [Abstract][Full Text] [Related]
35. Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.
Heidari A; Ghane Y; Heidari N; Hosseini S; Goodarzi A
Ther Adv Chronic Dis; 2024; 15():20406223241257342. PubMed ID: 38827348
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
37. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
Fotiadou C; Vakirlis E; Ioannides D
Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
[TBL] [Abstract][Full Text] [Related]
38. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Kimball AB; Loesche C; Prens EP; Bechara FG; Weisman J; Rozenberg I; Jarvis P; Peters T; Roth L; Wieczorek G; Kolbinger F; Jemec GBE
Exp Dermatol; 2022 Oct; 31(10):1522-1532. PubMed ID: 35638561
[TBL] [Abstract][Full Text] [Related]
39. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression.
Navrazhina K; Garcet S; Zheng X; Hur HB; Frew JW; Krueger JG
J Allergy Clin Immunol; 2022 Jan; 149(1):135-144.e12. PubMed ID: 34081946
[TBL] [Abstract][Full Text] [Related]
40. Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab.
McCormack S; Tazudeen N; Garden BC
Case Rep Dermatol Med; 2023; 2023():5189034. PubMed ID: 37908412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
